

# Pharmacovigilance Awareness For Healthcare Professionals

Jointly developed by:

The Institute of Pharmacovigilance

The International Society of Pharmacovigilance (ISoP) Special Interest Group on PV Professional Qualification Framework &







#### **Authors & Memebers of ISoP SIG**



# Current members of the ISoP SIG on PV Professional Qualification Framework

Petracek Jan Freeman Jana

Al-Zubiedi Sameh

**Badr Shahinaz** 

DeFilippo Elizabeth

Dewi Christiyanti

D'Souza Joan

Fouda Mohammed Ebrahim

Morad Mohammed

Ozioko Chidinma

Rostom Hadir

Saleh A. Hager Vasilieva Irina

Pikola Tomas

Uhlir Kamil

Kosturova Paulina

Abdulameer Al-Shimran Ban

Alashqar Amani Al-Zubiedi Sameh

Badr Shahinaz

DeFilippo Elizabeth Dewi Christiyanti

D'Souza Joan

Dzidzornu Ernest

Dioses Opalska Maria

Fouda Mohammed Ebrahim

Garcia Carla Haider Zaki Ibrahim Heba Jose Jimmy

Marin Danini

Mare Margaryta

Mohite Sachin

Morad Mohammed Nelavala Vineela

Ozioko Chidinma

Ortiz Jose Alberto

Petracek Jan

Rostom Hadir

Sameerah Shaikh Abdul Rahman

Saleh A. Hager

Swaminathan Manoj

Tregunno Phil Vasilieva Irina

Webley Sherael Webster Peggy

Younus Manal

Zhang Kai



## Content

 1
 1





Abbreviations	<u> </u>			
Glossary	<u>6</u>	<u></u> []	C)	(_)
<u>Professional Certification</u>	<u>7</u>	_	_	
Concept of levels	<u>9</u>			
<u>Prerequisites</u>	<u>11</u>			
<u>Knowledge</u>	<u>12</u>	П		
WHO Pharmacovigilance Core Curriculum	<u>14</u>	ַ ( )	בן (ו	



#### **Abbreviations**

AI Artificial intelligence

CV Curriculum Vitae

HCP Healthcare Professional

N/A Not applicable

UMC Uppsala Monitoring Centre

WHO World Health Organization



A stable, long-lasting, learnt predisposition to respond to certain things in a certain way. <sup>1</sup> A generic mix of knowledge, skills, and attitudes with broad application. <sup>2</sup> An industry-determined specification of competencies required for effective work performance. <sup>3</sup> An outcome of the assimilation of information through learning. Knowledge is the body of facts, principles, theories, and practices that is related to a field of study or work. <sup>4</sup> An acquired and practiced ability to carry out a task or job. <sup>2</sup>	Attitude	Competency	Competency standard	Knowledge	Skills
	learnt predisposition to respond to certain things	knowledge, skills, and attitudes with broad	specification of competencies required for effective work	assimilation of information through learning. Knowledge is the body of facts, principles, theories, and practices that is related to a field of	ability to carry out a task

<sup>&</sup>lt;sup>1</sup> EU Commission. Transferability of Skills across Economic Sectors. Luxembourg: Publications Office of the EU; 2011. DOI 10.2767/40404.

<sup>&</sup>lt;sup>2</sup> Tracey W, Bronstein D. The Human Resources Glossary: The Complete Desk Reference for HR Executives, Managers, and Practitioners. 3rd ed. St. Lucie Press; 2003.

<sup>&</sup>lt;sup>3</sup> Technical Education and Skills Development Authority. The TVET Glossary of Terms. 4th ed. Manila: Planning Office; 2010. ISBN 978-971-34-0207

<sup>4</sup> European Centre for the Development of Vocational Training, Terminology of European education and training policy. 2nd ed. Luxembourg: Publications Office of the EU; 2008. DOI: 10.2801/15877



**Pharmacovigilance Awareness for Healthcare Professionals** 

## **Professional Certification**





#### Here is how you can get certified

#### **Prerequisites**

All mandatory prerequisites are checked prior to the admission to the certification process via CV screening. The candidate might then be asked to provide further proofs on an individual basis (e.g., job descriptions, proof of employment, copies of documents, training records or recommendation letters).

#### Knowledge

The candidate's general and specific knowledge is evaluated via an online, AI proctored multiple-choice test. The content is derived from reference documents, pharmacovigilance regulations and legally binding documents specified in this guideline.

# Terms and conditions

The latest version of Terms and Conditions of GPPC, including detailed requirements for every role and region, can always be found on the Institute of Pharmacovigilance <u>website</u>.



## **Concept of levels**

Level	Expected knowledge
N/A	No knowledge required
Basic	Elementary knowledge level of the specific regulation; fundamental understanding of the terms and definitions used, a basic understanding of the concept of the regulation, general overview of what is included in the regulation and what topics it covers, where the regulation can be found and what situations and processes it applies to, passive/delegated usage of the regulation
Intermediate	Very good knowledge level of the specific regulation; unequivocal understanding and usage of the terms and definitions, complex understanding of the concept of the regulation, topics covered by it and its context regarding who/when/where/why/how it applies to, active usage of the regulation when required
Expert	Excellent knowledge of the specific regulation; sterling understanding and usage of the terms, in-depth knowledge of the concept of the regulation, detailed knowledge and comprehensive understanding of the topics covered by the regulation, who/when/where/why/how the regulation and its sections should be implemented and followed, as well as specific outcomes and responsibilities resulting from the regulation regarding all relevant stakeholders, active usage of the regulation on daily basis



## $\textbf{Concept of levels} - \underline{\textit{Example}}$

Level	Example of knowledge		
N/A	The candidate is not expected to have any knowledge about Pharmacovigilance, its definition, aim, and objectives. The test will not contain any questions reflecting this knowledge.		
Basic	Examples of expected basic knowledge of the candidate might be following what is pharmacovigilance, what is a "pharmacovigilance center", what information does an adverse reaction report contain, etc.	Question: Why are the results from clinical trials incomplete with regard to possible adverse reactions?  Answer: The number of patients and duration is limited.	
Intermediate	This level of knowledge is not required for this role.		
Expert	This level of knowledge is not required for this role.		

**Pharmacovigilance: Definition, aim, and objectives** 



### **Prerequisites**

#### **Mandatory prerequisites**

→ Healthcare Professional occupation or student (e.g., doctor, nurse, pharmacist, other HCPs)

#### Recommendations

- → Basic working proficiency in English
- → Computer literacy



### Knowledge

	General Knowledge	Level
1.	Pharmacovigilance definition, aim, and objectives <sup>5</sup>	•oo Basic
2.	Pharmacovigilance history <sup>6</sup>	•oo Basic
3.	Stakeholders in pharmacovigilance <sup>7</sup>	•oo Basic
4.	WHO UMC: Safety monitoring of medicinal products, Guidelines for setting up and running a Pharmacovigilance centre <sup>5</sup>	• o Basic

<sup>5</sup> WHO Uppsala Monitoring Centre. Safety monitoring on medicinal products, Guidelines for setting up and running a Pharmacovigilance Centre. Uppsala: Uppsala Monitoring Centre; 2000. ISBN 91630 9004 X

<sup>6</sup> M D B Stephens. The dawn of drug safety. Easton, Winchester, Hampshire England: George Mann Publications; 2012. ISBN 97 8 190764009 4

 $<sup>^{7}</sup>$  WHO Uppsala Monitoring Centre. The Importance of Pharmacovigilance. WHO; 2002. ISBN 92 41590157



## **Specific Knowledge**

	Chapter I. Regional Regulatory Specific Knowledge	Level
1.	Local regulatory authority guidance for HCPs (if applicable) *Optional; mandatory only for local certificate variants*	•oo Basic
	Chapter II. Role Specific Knowledge	
1.	WHO UMC: The Safety of Medicines in Public Health Programmes: Pharmacovigilance, an essential tool <sup>8</sup>	•oo Basic
2.	WHO UMC: Collecting high quality ADR reports (course available for HCPs)	•oo Basic
3.	WHO UMC: Essentials of pharmacovigilance communications (course available for HCPs)	•oo Basic

<sup>8</sup> WHO Uppsala Monitoring Centre. The Safety of Medicines in Public Health Programmes: Pharmacovigilance, an essential tool. WHO; 2006. ISBN 9241593911



#### WHO Pharmacovigilance Core Curriculum for University Teaching

PV Awareness for HCPs closely corresponds with the following summary of the key aspects and content of the WHO Pharmacovigilance Core Curriculum for University Teaching <sup>10</sup>

Knowledge element	Knowledge	Skills	Attitude
Understanding the importance of PV	V Drug-induced harm and hospital admission Recognizing ADRs and their impact on individual patients	Open mindedness of adverse outcomes of drug use in	
	Historical examples	patients	pharmacotherapy
Preventing ADRs	General risk factors	Choosing right drug treatment	Safe prescribing / dispensing
	Individual risk factors		
	Treatment guidelines and safety information		
Recognizing ADRs	ADR classification	Clinical and causality reasoning	Awareness of predictable and unexpected ADRs
	Risk factors		
	Confounding factors		
	Epidemiology		

10 van Eekeren R, Rolfes L, Koster A, Magro L, Parthasarathi G, Al Rammimy H, Schutte T, Tanaka D, van Puijenbroek E, Harmark L. What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects. Drug Saf. 2018; 41:1003-1011.



#### WHO Pharmacovigilance Core Curriculum for University Teaching

Knowledge element	Knowledge	Skills	Attitude
Managing ADRs	ADR classification	Choosing right actions	Optimize risk- benefit balance
	Seriousness	Patient and HCP communication	in an individual patient
	Severity	Recording of ADRs data	
Reporting ADRs	Limitations of premarketing phase  Recognizing ADRs in practice and reporting form completion		Responsibility for sharing (reporting) of ADRs
	Relevance of ADR reporting	completion	(reporting) of ADRS
	Documentation of ADRs		











# **Contact us**

**Institute of Pharmacovigilance** 

City Tower, Hvězdova 1716/2b Prague, Czech Republic, EU

info@pharmacovigilance.institute

**GET CERTIFIED NOW!** 

















We always welcome your comments and input; if you have any please send us an email.

Thank you for your contribution to the pharmacovigilance profession!

Team of authors